The Netherlands
EYE PCR BV is a health care startup based in The Netherlands with a mission to bring extraordinary science to life-changing therapies for patients with eye disorders. Established in 2018, the company is focused on pioneering innovation in the field of cataract and refractive lens exchange surgeries.
The company's flagship product, fixOflexTM, is a novel intraocular ophthalmic implant designed to reconstruct and hold the human lens capsule, addressing complications often associated with traditional procedures. EYE PCR aims to provide personalized care tailored to individual patient needs, ultimately improving patient satisfaction and outcomes.
EYE PCR's dedication to innovation and scientific research positions it at the forefront of advancements in eye care. The company's vision is to create a renowned scientific environment built on trust, providing high-tech solutions to improve and preserve the sense of sight.
As venture capital assessors, potential investment in EYE PCR BV presents an opportunity to support groundbreaking developments in the treatment of eye disorders. The company's commitment to leveraging science and technology to enhance patient outcomes aligns with the increasing demand for innovative solutions in the healthcare industry.
